CORAL SPRINGS, Fla., Dec. 19, 2012 (GLOBE NEWSWIRE) — Nutra Pharma Corp. (NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be introducing a stronger version of its over-the-counter (OTC) pain reliever, Nyloxin(TM). The new product will be called Nyloxin(TM) Military Strength.
Over the past few years, the U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications, particularly opiates. In 2009, close to 3.8 million prescriptions for pain relievers were written in the military. This staggering number was more than a 400% increase from the number of prescriptions written in the military in 2001. But prescription drugs are not the only issue. The most common and seemingly harmless way to treat pain is with non steroidal, anti-inflammatory drugs (NSAIDS). But there are risks. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction and life-threatening allergic reactions can occur. It is reported that approximately 7,600 people in America die from NSAID use and some 78,000 are hospitalized.
Ibuprofen, also an NSAID has been of particular concern in the military. The terms “Ranger Candy” and “Military Candy” refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain. But when taking anti-inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake.
“Our hope is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military,” said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Our goal for Nyloxin over the next several years is to be the number one choice that people turn to for chronic pain relief,” he concluded.
Nyloxin(TM) is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin(TM) is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin(TM) is also offered in an extra strength formula for more advanced, Stage 3, chronic pain. The new Nyloxin(TM) Military Strength represents the strongest version of Nyloxin(TM) available.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin(R) and Nyloxin(TM). For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The introduction of Nyloxin(TM) Military Strength should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company‘s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact:
Nutra Pharma Corp.
Nina Goldstein
877-895-5647
[email protected]
This information was brought to you by Cision http://www.cisionwire.com
http://www.cisionwire.com/nutra-pharma-corporation/r/nutra-pharma-introduces-nyloxin–military-strength,c9350866
Sexual Health News Headlines – Yahoo! News
Title Post: Nutra Pharma Introduces Nyloxin(TM) Military Strength
Rating:
100%
based on 99998 ratings.
5 user reviews.
Author:
Thanks for visiting the blog, If any criticism and suggestions please leave a comment
Nutra Pharma Introduces Nyloxin(TM) Military Strength
This article
Nutra Pharma Introduces Nyloxin(TM) Military Strength
can be opened in url
http://newstipie.blogspot.com/2012/12/nutra-pharma-introduces-nyloxintm.html
Nutra Pharma Introduces Nyloxin(TM) Military Strength
